Thermo Fisher Scientific Inc.
TMO · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,122,000 | $10,855,000 | $10,364,000 | $11,395,000 |
| % Growth | 2.5% | 4.7% | -9% | – |
| Cost of Goods Sold | $6,470,000 | $6,807,000 | $6,119,000 | $6,928,000 |
| Gross Profit | $4,652,000 | $4,048,000 | $4,245,000 | $4,467,000 |
| % Margin | 41.8% | 37.3% | 41% | 39.2% |
| R&D Expenses | $347,000 | $352,000 | $342,000 | $374,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,365,000 | $1,779,000 | $2,063,000 | $1,825,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,712,000 | $2,131,000 | $2,405,000 | $2,199,000 |
| Operating Income | $1,943,000 | $1,917,000 | $1,840,000 | $2,268,000 |
| % Margin | 17.5% | 17.7% | 17.8% | 19.9% |
| Other Income/Exp. Net | -$115,000 | -$206,000 | -$234,000 | -$294,000 |
| Pre-Tax Income | $1,828,000 | $1,711,000 | $1,606,000 | $1,974,000 |
| Tax Expense | $207,000 | $92,000 | $95,000 | $150,000 |
| Net Income | $1,616,000 | $1,617,000 | $1,507,000 | $1,830,000 |
| % Margin | 14.5% | 14.9% | 14.5% | 16.1% |
| EPS | 4.28 | 4.28 | 3.99 | 4.79 |
| % Growth | 0% | 7.3% | -16.7% | – |
| EPS Diluted | 4.27 | 4.28 | 3.98 | 4.78 |
| Weighted Avg Shares Out | 378,000 | 378,000 | 378,000 | 382,845 |
| Weighted Avg Shares Out Dil | 378,000 | 378,000 | 379,000 | 383,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $234,000 | $297,000 | $203,000 | $227,000 |
| Interest Expense | $347,000 | $404,000 | $303,000 | $384,000 |
| Depreciation & Amortization | $663,000 | $685,000 | $705,000 | $742,000 |
| EBITDA | $2,838,000 | $2,798,000 | $2,628,000 | $3,068,000 |
| % Margin | 25.5% | 25.8% | 25.4% | 26.9% |